Background The objective of this open-label, preliminary study was to assess the efficacy of
omega-3 fatty acids for treating dyslipidemia associated with use of atypical antipsychotics.
Methods Participants treated with atypical antipsychotics who had hypertriglyceridemia (>
200 mg/dL) and/or hypercholesterolemia (> 250 mg/dL) were enrolled in an open trial and
received omega-3 fatty acids (Lovaza) for up to 16 weeks. Serum lipid profiles were re-
assessed at 8 and 16 weeks. Results Twenty-eight participants with dyslipidemia enrolled in …

RESULTS: Twenty-eight participants with dyslipidemia enrolled in the trial; 16 were
evaluable with post-baseline assessments. There was an average decrease in triglyceride
levels of 54.13 t 8344 mg/dL (P=. 04). A more pronounced benefit of omega-3
supplementation was observed in participants with elevated triglyceride levels atbaseline (>
200 mg/dL), compared with those with elevated cholesterol values but normal or more
modestly elevated triglyceride levels at enrollment. Participants with hypertriglyc-eridemia at …